Cytotoxic drugs and the CD95 pathway

Leukemia

Volumn 13, Issue 11, 1999, Pages 1854-1858

  Friesen, C ^b   Fulda, S ^b   Debatin, K M ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b NONE

Author keywords

Apoptosis; CD95; CD95 ligand; Chemosensitivity; Cytotoxic drugs; Resistance

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CISPLATIN; CYTARABINE; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; FAS ANTIGEN; FAS LIGAND; METHOTREXATE; RECEPTOR;

APOPTOSIS; CELL DEATH; CONFERENCE PAPER; CROSS LINKING; DRUG RESISTANCE; ENZYME ACTIVATION; LEUKEMIA; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SOLID TUMOR; TARGET CELL;

EID: 0032742205     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401333     Document Type: Conference Paper

References (57)

1. Chabner BA, Myers CE. Clinical pharmacology of cancer chemotherapy. In: de Vita VTJ, Hellmann S, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology. Lippincott: Philadelphia, 1989, pp 349-378.
2. Kerr JFR, Willie AH, Currie AR. Apoptosis a basic biological phenomenon wilh wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-257.
3. Trauth BC, Klas C, Peter AMJ, Matz S, Möller P, Falk W, Debatin KM, Krammer PH. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301-305.
4. Debatin KM, Goldman CK, Bamford R, Waldmann TA, Krammer PH. Monoclonal antibody-mediated apoptosis in adult T cell leukemia. Lancet 1990; 335: 497-500.
5. Debatin KM, Goldman CK, Waldmann TA, Krammer PH. APO-1 induced apoptosis of leukemia cells from patients with adult T cell leukemia. Blood 1993; 81: 2972-2977.
6. Krammer PH, Dhein J, Walczak H, Behrmann I, Mariani S, Matiba B, Fath M, Daniel PT, Knipping E, Westendorp MO, Stricker K, Bäumler C, Hellbardt S, Germer M, Peter ME, Debatin KM. The role of APO-1-mediated apoptosis in the immune system. Immunol Rev 1994; 142: 175-191.
7. Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, LiWeber M, Richards S, Dhein J, Trauth BC, Ponstingl H, Krammer PH. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. J Biol Chem 1992; 267: 10709-10715.
8. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto K, Nagat S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233-243.
9. Klas C, Debatin KM, Jonker RR, Krammer PH. Activation interferes with the apoptotic pathway in mature human T cells, Intl Immunol 1993; 5: 625-630.
10. Kischkel FC, Hellbardt S, Behrmann I, Gremer M, Pawlita M, Krammer PH, Peter M. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins (CAP) form a death-inducing signalling complex (DISC) with the receptor. EMBO J 1995; 14: 5579-5588.
11. Debatin KM. Disturbances of the CD95 (APO-1/Fas) system in disorders of lymphohaematopoietic cells. Cell Death Differ 1996; 3: 185-189.
12. Peter ME, Kischkel FC, Hellbrandt S, Chinnaiyan AM, Krammer PH, Dixit VM. CD95 (APO-1/Fas)-associating signaling proteins. Cell Death Differ 1996; 3: 161-170.
13. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT-1/FADD-interacting protease, in Fas/APO-1-and TNF receptor-induced cell death. Cell 1996; 85: 803-815.
14. Muzio M, Salvesen GS, Dixit VM. Flice induced apoptosis in a cell-free system. J Biol Chem 1997; 272: 2952-2956.
15. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME, Dixit VM. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996; 85: 817-827.
16. Bellgrau D, Gold D, Selawry P, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377: 630-632.
17. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism for immun pivilege. Science 1995; 270: 1189-1192.
18. Suda T, Takahashi S, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-1178.
19. Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J 1995; 14: 1129-1135.
20. Dhein J, Walczak H, Bäumler C, Debatin KM, Krammer PH. Autocrine T cell suicide mediated by APO-1 (Fas/CD95). Nature 1995; 373: 438-441.
21. Kroemer G. The proto-oncogene bcl-2 and its role in regulation of apoptosis. Nature Med 1997; 3: 614-620.
22. Reed JC. Double identity for proteins of the Bcl-2 family. Nature 1997; 387: 773-776.
23. Yang E, Korsmever SJ. Molecular thanatopsis: a discourse on the Bcl-2 family and cell death. Blood 1996; 88: 386-401.
24. s sensitizes MCF-7 cells to chemotherapyinduced apoptosis. Cancer Res 1995; 55: 2507-2510.
25. 1 is expressed in neuroblastoma cells und modulates chemotherapy-induced apoptosis. Cancer Res 1995; 55: 2576-2582.
26. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapyinduced apoptosis in a human leukemia cell line. Blood 1993; 81: 151-157.
27. Scaffidi CA, Fulda S, Srinivasan A, Friesen C, Feng L, Tomaselli KJ, Debatin K-M, Krammer PH, Peter ME. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998; 17: 1675-1687.
28. Li H, Zhu H, Xu C-J, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the fas pathway of apoptosis. Cell 1998; 94: 491-501.
29. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998; 94: 481-490.
30. Kuwana T, Smith JJ, Muzio M, Dixit V, Newmeyer DD, Kornbluth S. Apoptosis induction by caspase-8 is amplified through the mitochondrial release of cytochrome c. J Biol Chem 1998; 273: 16589-16594.
31. Nagata S. Apotosis by death factor. Cell 1997; 88: 355-365.
32. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schröter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190-195.
33. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med 1996; 2: 574-577.
34. Müller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, Stremmel W, Krammer PH, Galle P. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wilde-type p53. J Clin Invest 1997; 99: 403-413.
35. Fulda S, Sieverts H, Friesen C, Herr I, Debatin K-M. The CD95 (APO-1/Fas) system mediates drug induced apoptosis in neuroblastoma cells. Cancer Res 1997; 57: 3823-3829.
36. Fulda S, Los M, Friesen C, Debatin KM. Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int J Cancer 1998; 76: 105-114.
37. Friesen C, Fulda S, Debatin KM. Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells. Leukemia 1997; 11: 1833-1841.
38. Kasibatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A, Green DR. DNA damaging agents induce expression of FAS ligand and subsequent apoptosis in T lymphocytes via activation of NFB. Mol Cell 1998; 1: 543-551.
39. Los M, Herr I, Friesen C, Fulda S, Schulze-Osthoff K, Debatin KM. Crossresistance of CD95-and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood 1997; 90: 3118-3129.
40. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GC, Salvesen GS, Dixit VM. Yama/CPP32 a mammalian homolog of Ced-3, is a CrmA-inhibitable protease that cleaves the death substrate poly (ADP-ribose) polymerase. Cell 1995; 81: 801-809.
41. Min YH, Lee S, Lee JW et al Expression of FAS antigen in acute myeloid leukemia is associated with therapeutic response to chemotherapy. Br J Haematol 1996; 93: 928-930.
42. Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel MT. Sensitization of cancer cells treated with cytotoxic drugs to FAS-mediated cytotoxicity. J Natl Cancer Inst 1997; 89: 783-789.
43. Debatin KM. Cytotoxic drugs, programmed cell death, and the immune system: defining new roles in an old play. J Natl Cancer Ins 1997; 89: 750-751.
44. Yoshiro K, Zhou YW, Zhan XL et al. Fas/APO-1 (CD95)-mediated cytotoxicity is responsible for the apoptotic cell death of leukaemic cells induced by interleukin-2-activated T-cells. Br J Haematol 1997; 96: 147-157.
45. Goldstein LT, Ozlos RF (eds). Anticancer Drug Resistance: Advances in Molecular and Clinical Research. Kluwer Academic Publishers: Massachusetts, 1994.
46. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994; 78: 539-542.
47. Kroemer G, Zamzami N, Susin SA. Mitochondrial control of apoptosis. Immunol Today 1997; 18: 44-51.
48. Zamzami N, Susin SA, Marchetti P, Hirsch T, Gomez-Monterrey J, Castedo M, Kroemer G. Mitochondrial control of nuclear apoptosis. J Exp Med 1996; 183: 1533-1544.
49. L antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res 1997; 57: 62-67.
50. Itoh N, Tsujimoto Y, Nagata S. Effect of Bcl-2 on Fas antigenmediated cell death, J Immunol 1993; 151: 621-627.
51. Pastan I, Gottesmann MM. Multidrug resistance in human cancer. New Engl J Med 1987; 316: 1388-1393.
52. Gottesmann MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
53. Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang WW, Kruzel E, Radinsky R. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 1995; 15: 3032-3040.
54. Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung SJ, Earnshaw WC, Leibson PJ, Kaufmann SH. Comparison of apoptosis in wildtype and fas-resistant cells: chemotherapy-induced apoptosis is not dependent on fas/fas ligand interaction. Blood 1997; 90: 935-943.
55. Villunger A, Egle A, Kos M, Hartmann BL, Stephan G, Kofler R, Greil R. Drug-induced apoptosis is associated with enhanced fas (Apo-1/CD95) ligand expression but occurs independently of fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res 1997; 57: 3331-3334.
56. Tolomeo M, Dusonchet I, Meli M, Grimaudo S, D Alessandro N, Papoff G, Ruberti G, Rausa L. The CD95/CD 95 ligand system is not the major effector in anticancer drug-mediated apoptosis. Cell Death Differ 1998; 5: 735-742.
57. McGahon AJ, Pereira Costa AP, Daly L, Cotter TG. Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of Fas (APO-1/Cd95) receptor/ligand system. Br J Haematol 1998; 101: 539-547.